Long-term Antibiotic Therapy in Stable COPD

• Research type

  Research Study

• Full title

  A Phase III single-blind, randomised, placebo controlled trial of long term therapy in patients with stable COPD using Moxifloxacin, Azithromyin, and Doxycycline: a Bayesian decision analysis, including other criteria, will be used to distinguish the optimal antibiotic treatment.

• IRAS ID

  73333

• Sponsor organisation

  UCL

• Eudract number

  2011-001063-43

• Research summary

  Chronic Obstructive Pulmonary Disease (COPD) is the cause of considerable deaths, and exacerbations (flare-up of symptoms) are a major cause of hospital admission in the UK. Bacterial infections play an important role in the development of COPD, however, there is little information available about the use of long term antibiotics in the treatment of this disease. Therefore the purpose of this study is to identify the best antibiotic regime for treating patients with COPD who have persistent bacterial infection in their lung. We will test a variety of approaches including both older and newer regimes prescribed either on a daily basis at a lower dose or in ??pulsed? courses (for example, every other day or five days every month). The three antibiotics tested in this study are: moxifloxacin, azithromcyin and doxycycline. This is a 13 weeks study conducted at the Royal Free Hospital, London. It is expected that approximately 200 patients will be selected for this study from GP practices up to a 15 mile range from the Royal Free Hospital. The information we get from this study may help us to treat future patients with COPD better.

• REC name

  London - Dulwich Research Ethics Committee

• REC reference

  11/LO/0932

• Date of REC Opinion

  8 Sep 2011

• REC opinion

  Further Information Favourable Opinion